IPO Details#
Seaport Therapeutics Inc. has officially priced its initial public offering (IPO) at $18.00 per share. The company plans to sell 14,160,000 shares, reaching the top of its target price range. This move is expected to generate gross proceeds of approximately $254.9 million, which will be used to support its operations and growth.
Financial Health#
Currently, Seaport Therapeutics has a market capitalization of $64.3 million. The company’s current ratio stands at 1.86, indicating that it has enough assets to cover its short-term liabilities, which is a sign of healthy liquidity. Additionally, the company has given underwriters a 30-day option to buy an extra 2,124,000 shares at the IPO price, minus any underwriting fees.
Trading Information#
Shares of Seaport Therapeutics are set to begin trading today on the Nasdaq Global Select Market under the ticker symbol SPTX. The offering is anticipated to close on May 4, 2026, pending standard closing conditions.
Company Focus#
Seaport Therapeutics specializes in developing treatments for mental health conditions such as depression and anxiety. The company utilizes its unique Glyph platform to create oral therapies that target established clinical mechanisms. Over the past year, Seaport has reported impressive revenue growth of 197%, showcasing its potential in the therapeutics market.
A registration statement for the offering was filed with the Securities and Exchange Commission and was approved on April 30, 2026.